A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma

This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Intervention(s):

  • drug : AMG 655
  • drug : Doxorubicin
  • other : Placebo

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Histologically or cytologically confirmed soft tissue sarcoma - Locally advanced, recurrent, or metastatic, unresectable disease - Measurable disease according to modified RECIST - ECOG performance status of 0 or 1 - Men or women at least 18 years of age - Adequate hematological, renal, hepatic, and coagulation function

External Links

Explore related trials

Contact information

Primary Contact:

Maria Ahern 6507256413

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: